Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of KRN125 for chemotherapy-induced neutropenia in breast cancer
jRCT2080220922Phase 2
- Sponsor
- Kyowa Kirin
- Start
- Nov 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of pegfilgrastim in breast cancer and chemotherapy-induced neutropenia (CIN), sponsored by Kyowa Kirin.
02
Drugs
pegfilgrastim
03
Conditions
breast cancerchemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on jRCT2080220922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220922.